Meet the people who make Transposagen a leader in genetically modified animal models, cell engineering services, and gene editing tools.
Mr. Isett joined Transposagen in August 2017 as a management consultant and has since helped to lead the Company to an expansion into the bioprocess market with the launch of new products, services, and licensing programs. Previously, he led business units for GE, Lonza, and BD ranging in size from $50-500M. Tom was the founder of BD’s Advanced Bioprocessing business, Commence Bio, Inc. (a cellular immunotherapy innovator), and i.e. Advising, LLC, a life science strategy and management consultancy that supports Fortune 500s, PE firms, and biotechs, alike.
Tom also leads Hera BioLabs, a Transposagen spinout that uses the Super piggyBacTM Transposon System and Cas-CLOVER TM CRISPR System to create its novel animal model platforms for its pre-clinical CRO services. He presently serves on the Board of Directors for Commence Bio, Inc. and is active as an NHLBI reviewer and member of their National Mentor Network. Tom has been an invited speaker on the topics of protein and cell bioprocessing, as well as commercial leadership. Tom is a cum laude graduate of Drexel University with a BSc. in Biological Sciences.
Dr. Tseten Yeshi
Head of Molecular Biology
Dr. Yeshi is a molecular biologist and an expert in genome editing, with full range experience in performing complex gene editing in a broad array of cell types including rodent embryonic stem cells and spermatogonial stem cells. He has worked extensively in development of proprietary modifications in the architecture of piggyBac, TALENs and CRISPR/Cas genome modification tools and combining these technologies for efficient Footprint Free Gene editing: making precise mutations without leaving any undesired changes or “footprint” behind in the genome. Dr. Yeshi has well-developed scientific program management skills and experience, has been a Principle Investigator on multiple NIH SBIR grants and a co-inventor of several patents.
Dr. Valeriya Steffey
Director, Cell Line Engineering
Dr. Valeriya Steffey has worked for Transposagen Biopharmaceuticals Inc. for seven years, where she has distinguished herself as an innovative leader in both technology and business development. Dr. Steffey is the Director of Cell Line Engineering at Transposagen. Under her management, her team has a proven track record of successful completion of cell line engineering, engineered animal models and R&D projects. As Director, she creates relationships and liaises with customers in academia and industry to initiate and manage projects. As a leader at Transposagen, she oversees new product development.
In addition to her experience in the biotechnology industry, Dr. Steffey practiced medicine for over ten years and performed academic research, with an emphasis in anatomy and neurobiology, providing her with a broad and varied background. She is a published author and co-author of many scientific articles.